Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

New research being presented at the European Congress on Obesity (ECO 2025) has found that patients of an online obesity ...

Embla today announced results from a 64-week real-world study presented at the European Congress on Obesity, tracking nearly 2,700 adults in a digital GLP-1 treatment program. The study found that ...